Want to see JP:4893 full AI Analyst Report?
Noile-Immune Biotech Inc. (4893) AI Stock Analysis
Noile-Immune Biotech Inc.
(TSE/TYO:4893)
The overall score is at the minimum of 37, reflecting a convergence of significant risks. The company is a pre-revenue biotech with deep operating losses and negative cash flows, though its debt-free balance sheet provides a temporary buffer. Technicals are extremely weak, with the stock in a deep downtrend and oversold conditions. The negative P/E and lack of dividend further underscore the lack of current profitability. The primary risk is continued cash burn without commercial traction.
Noile-Immune Biotech Inc. (4893) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.56B
- Dividend Yield
- ―
- Average Volume (3M)
- 193.04K
- Price to Earnings (P/E)
- -4.7
- Beta (1Y)
- 0.80
- Revenue Growth
- -92.30%
- EPS Growth
- -8.80%
- Country
- Japan
- Employees
- 23
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Noile-Immune Biotech Inc. Business Overview & Revenue Model
Company Description
Established in 2015 and based in Minato, Japan, this company is dedicated to exploring and advancing CAR-T cell technology for use in cancer immunotherapy treatments.
Noile-Immune Biotech Inc. Financial Statement Overview
Summary
Financial performance is weak. The Income Statement Score (10) reflects volatile, declining revenue and deep operating losses. The Cash Flow Score (20) shows persistent negative operating cash flow. These are partially offset by a strong Balance Sheet Score (65) with no debt and a solid equity base. Overall, the company is burning cash with minimal revenue, a high-risk profile typical of early-stage biotech.
Income Statement
10Very NegativeBalance Sheet
65PositiveCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 715.00K | 5.00M | 7.59M | 316.82M | 625.78M | 100.73M |
| Gross Profit | 0 | 5.00M | 7.39M | 314.56M | 618.71M | 77.83M |
| EBITDA | -800.73M | -797.25M | -1.07B | -775.39M | -106.34M | -767.51M |
| Net Income | -753.88M | -793.54M | -964.46M | -1.13B | -386.62M | -795.03M |
Balance Sheet | ||||||
| Total Assets | 3.66B | 4.01B | 4.80B | 5.78B | 4.64B | 4.27B |
| Cash, Cash Equivalents and Short-Term Investments | 3.54B | 3.92B | 4.67B | 5.56B | 4.52B | 4.14B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 90.34M | 79.64M | 74.67M | 91.49M | 340.42M | 85.72M |
| Stockholders Equity | 3.57B | 3.93B | 4.73B | 5.69B | 4.30B | 4.19B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 0 | -887.81M | -873.08M | -107.18M | -777.14M |
| Operating Cash Flow | 0 | -752.22M | -887.81M | -873.08M | -107.18M | -777.14M |
| Investing Cash Flow | 0 | -378.00K | 557.00K | -5.32M | 0 | -4.03M |
| Financing Cash Flow | 0 | -20.00K | 2.50M | 1.91B | 487.62M | 2.37B |
Noile-Immune Biotech Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4893, the sentiment is Negative. The current price of 82.00 is below the 20-day moving average (MA) of 94.40, below the 50-day MA of 120.58, and below the 200-day MA of 137.66, indicating a bearish trend. The MACD of -10.25 indicates Negative momentum. The RSI at 15.32 is Positive, neither overbought nor oversold. The STOCH value of 18.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4893.
Noile-Immune Biotech Inc. Peers Comparison
Overall Rating
JP:375045Neutral
JP:488045Neutral
JP:456442Neutral
JP:459942Neutral- JP:489337Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:3750 | 45Neutral | JPY 7.14B | -12.36 | ― | ― | 15.47% | 69.34% |
| JP:4880 | 45Neutral | JPY 5.68B | 56.94 | ― | 1.75% | -9.94% | ― |
| JP:4564 | 42Neutral | JPY 7.35B | -7.20 | -42.79% | ― | -8.58% | 19.03% |
| JP:4599 | 42Neutral | JPY 8.71B | -4.51 | ― | ― | ― | 4.85% |
| JP:4893 | 37Underperform | JPY 3.69B | -4.71 | ― | ― | -92.30% | -8.80% |
| JP:7776 | 37Underperform | JPY 7.43B | -6.32 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4893 | Noile-Immune Biotech Inc. | 82.00 | -70.00 | -46.05% | |
| JP:4564 | OncoTherapy Science, Inc. | 17.00 | -7.00 | -29.17% | |
| JP:3750 | Cytori Cell Research Institute, Inc. | 776.00 | -64.00 | -7.62% | |
| JP:4599 | StemRIM Inc. | 134.00 | -139.00 | -50.92% | |
| JP:4880 | CellSource Co., Ltd. | 283.00 | -228.00 | -44.62% | |
| JP:7776 | CellSeed Inc. | 183.00 | -254.00 | -58.12% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026